<DOC>
	<DOCNO>NCT02038803</DOCNO>
	<brief_summary>Inhaled tobramycin Cystic Fibrosis Foundation recommend effective treatment individual cystic fibrosis management Pseudomonas aeruginosa airway colonization improve FEV1 reduces number acute pulmonary exacerbation CF . Patients typically use inhaled tobramycin period 28 day . Unfortunately , standard nebulizer method deliver tobramycin inhale solution ( TIS ) time-consuming may result missed therapy dose suboptimal care . A new inhaled formulation delivery device , TOBI Podhaler ( TPI ) , quicker , efficient method administer inhaled Tobramycin . This new pocket-sized disposable inhaler maintenance free , require refrigeration power source , greatly increase patient mobility improve time management .</brief_summary>
	<brief_title>Efficacy TOBI Podhaler vs. Tobramycin Inhalation Solution</brief_title>
	<detailed_description>Adult cystic fibrosis patient Rush University Medical Center Adult Cystic Fibrosis Program recruit prospective cohort study evaluate patient preference either TOBI Podhaler inhale tobramycin solution compare efficacy TOBI Podhaler tobramycin inhale solution . This project evaluate potential difference efficacy , medication adherence , treatment time , side effects/adverse effect , quality life , identify patient preference use TIP TIS . Measurements 28-day cycle tobramycin inhaled solution , first 28-day cycle TOBI Podhaler third 28-day cycle TOBI Podhaler include FEV1 , number acute pulmonary exacerbation , adherence , cough frequency , sputum characteristic , side effect adverse event . The quality life assess Cystic Fibrosis Questionnaire-Revised ( CFQ-R ) measure 28-day cycle tobramycin inhaled solution third 28-day cycle TOBI Podhaler . The FEV1 value , number miss treatment , total treatment time analyze repeated measure analysis variance . Comparisons CFQ-R data switch TPI make Student 's t-test . The chi square test use evaluate difference categorical data . All test test alpha equal 0.05 . Responses adverse reaction side effect list categorize . The percentage patient prefer inhaled solution report .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>1 . Adult ( â‰¥ 18 year ) diagnose cystic fibrosis 2 . Airway colonization Pseudomonas aeruginosa sensitive tobramycin vitro currently manage Tobramycin inhaled solution interested switch TOBI Podhaler . 1 . Persons unable communicate English , 2 . Pregnant patient , 3 . Patients &lt; 18 year age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Cystic Fibrosis Medication Adherence</keyword>
</DOC>